BioMimetic's Augment Bone Graft Goes To Panel In May
This article was originally published in The Gray Sheet
Executive Summary
FDA's Orthopedic and Rehabilitation Devices panel will meet May 12 to discuss a pre-market approval application for BioMimetic Therapeutics’ Augment fully synthetic bone graft, the firm announced Jan. 31.